Clinical Report: Real-World, Digital-First GLP-1 Receptor Agonist Treatment for Women
Background
Obesity is associated with type 2 diabetes, cardiovascular disease, hepatic dysfunction, other chronic conditions, and substantial quality-of-life and healthcare burdens. GLP-1RAs and other incretin-based treatments have produced clinically meaningful weight reduction and improved cardiometabolic risk factors in randomized trials, including among people without diabetes. The article notes that access in many care settings remains limited and that large cardiometabolic outcomes trials have recruited mainly men, although women make up most GLP-1RA users in routine and community care. It presents digitally enabled care as a potential delivery framework while noting that robust real-world evidence remains limited.
Data Highlights
Measure
Reported data
Initial screening criteria met
16,121 individuals
Excluded for incomplete baseline blood testing
4,025
Further exclusions after clinical review
308
Analytic cohort with therapy prescribed and dispatched
8,127 participants
Recruitment period
27 November 2024–31 January 2025
Age range
18–79 years
Participants aged 30 to <60 years
82.1%
Participants identified as white
88.0%
Key Findings
The analytic cohort comprised 8,127 adult women, defined as female at birth, who had GLP-1RA therapy prescribed and dispatched before the administrative cutoff.
Recruitment used digital outreach from 27 November 2024 to 31 January 2025, followed by structured digital onboarding, laboratory testing, and clinical review.
Of 16,121 individuals meeting initial screening criteria, 4,025 were omitted solely because baseline blood testing was incomplete; a further 308 were excluded after clinical review for abnormal laboratory results or medical exclusion criteria.
Participants were aged 18–79 years; 82.1% were aged 30 to <60 years, and 88.0% were white. The excerpt states that other ethnic groups were represented but does not provide their proportions.
The care model required monthly questionnaires before refill approval, weekly live-video check-ins with trained proctors, supervised confirmation of weight and medication scanning, and monthly clinician-led assessment for individualized, response-guided dose titration.
The program also provided structured side-effect mitigation and evolving educational material accessible throughout treatment. The supplied excerpt does not include weight-loss, adherence, tolerability, or other treatment outcome results.
Clinical Implications
The described program offers a detailed example of remote GLP-1RA delivery incorporating recurring monitoring, clinician-led dose assessment, and side-effect support. The available excerpt establishes cohort size and program procedures but does not provide clinical outcome data with which to assess effectiveness or safety.
Conclusion
This large community-based program enrolled more than 8,000 women into a structured digital-first GLP-1RA care pathway. Further interpretation of treatment effects is not possible from the supplied excerpt because outcome results are not included.
